- Home
- FRD vs MGNX Comparison
FRD vs MGNX Comparison
Compare FRD & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRD
- MGNX
- Stock Information
- Founded
- FRD 1965
- MGNX 2000
- Country
- FRD United States
- MGNX United States
- Employees
- FRD N/A
- MGNX N/A
- Industry
- FRD Steel/Iron Ore
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- FRD Industrials
- MGNX Health Care
- Exchange
- FRD Nasdaq
- MGNX Nasdaq
- Market Cap
- FRD 119.5M
- MGNX 70.3M
- IPO Year
- FRD N/A
- MGNX 2013
- Fundamental
- Price
- FRD $16.17
- MGNX $1.54
- Analyst Decision
- FRD
- MGNX Hold
- Analyst Count
- FRD 0
- MGNX 10
- Target Price
- FRD N/A
- MGNX $6.83
- AVG Volume (30 Days)
- FRD 20.1K
- MGNX 629.1K
- Earning Date
- FRD 06-10-2025
- MGNX 05-20-2025
- Dividend Yield
- FRD 1.00%
- MGNX N/A
- EPS Growth
- FRD N/A
- MGNX N/A
- EPS
- FRD 0.81
- MGNX N/A
- Revenue
- FRD $447,616,000.00
- MGNX $149,962,000.00
- Revenue This Year
- FRD N/A
- MGNX N/A
- Revenue Next Year
- FRD N/A
- MGNX $80.86
- P/E Ratio
- FRD $19.70
- MGNX N/A
- Revenue Growth
- FRD N/A
- MGNX 155.26
- 52 Week Low
- FRD $12.24
- MGNX $0.99
- 52 Week High
- FRD $19.18
- MGNX $14.91
- Technical
- Relative Strength Index (RSI)
- FRD 48.38
- MGNX 47.79
- Support Level
- FRD $14.00
- MGNX $1.54
- Resistance Level
- FRD $17.73
- MGNX $1.82
- Average True Range (ATR)
- FRD 0.74
- MGNX 0.16
- MACD
- FRD -0.14
- MGNX 0.02
- Stochastic Oscillator
- FRD 58.18
- MGNX 55.28
About FRD Friedman Industries Inc.
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.